The Auckland Dry Eye Epidemiology Study is a large population-based, multi-arm, cross-sectional study based at the Ocular Surface Laboratory (OSL) at the University of Auckland. It aims to characterise modifiable and non-modifiable risk factors of dry eye disease (DED) and address some of the gaps i
The addition of data on novel autoantibodies may improve the accuracy of screening dry eye patients for Sjögren’s syndrome, according to research led by Dr Vatinee Bunya from the Penn Dry Eye and Ocular Surface Center in the US.
More than 150 participants from 37 countries are beginning work on the latest Tear Film and Ocular Surface Society (TFOS) workshop, A Lifestyle Epidemic: Ocular Surface Disease. The workshop will be led by a steering committee comprising executive members, Professors Jennifer Craig (chair, New Zeala
Inflammation is a key feature of the self-perpetuating vicious circle in the evaporative and aqueous forms of dry eye disease. Therapeutics aim to break this cycle and reinstate tear film and ocular surface homeostasis. But given today’s vast range of available and developing therapeutic options, ad
The BCLA virtual conference was a breath of fresh air. Organisers took a arranged four back-to-back sessions over a 30-hour period, giving members from across the world the benefit of 'live' sessions.
Meibomian gland dysfunction (MGD) is characterised by alterations in glandular secretion and terminal duct obstruction, secondary to hyperkeratinisation of the ductal epithelium1. The oils secreted from the glands contain a mixture of lipid secretions and keratinised epithelial debris. Keratin level
Placement - Dry eye special feature, dry eye-focused news brief to fill any gaps from middle to end – say p36-49 – please use this one
A report by The Business Research Company predicts that the global dry eye medication market will grow to around US$4.8bn in 2025, up from US$2.9bn in 2015.
According to the large Dry Eye Assessment and Management (DREAM) study, patients with facial rosacea and peripheral artery disease experience more severe dry eye disease symptoms.
Dry eye disease (DED) is one of the most common yet undertreated ocular surface conditions. The Tear Film and Ocular Surface Society’s second Dry Eye Workshop (TFOS DEWS II) recognised DED as a multifactorial, self-perpetuating vicious circle characterised by tear film instability and hyperosmolarit
The mainstay therapy for dry eye disease (DED) is the use of artificial tear solutions to supplement the natural tear film1. The therapeutic landscape has recently seen a considerable evolution of
Self-reported symptoms of mask-associated dry eye